iconiifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Zydus Lifesciences Surges 2% as US FDA Grants Final Approval for Heart Drug Ivabradine

1 Dec 2023 , 03:13 PM

Zydus Lifesciences experienced a 2% surge on December 1 following the US Food and Drug Administration's final approval for a heart drug. Ivabradine, the approved drug, reduces the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure featuring reduced left ventricular ejection fraction. 

Zydus Lifesciences traded at Rs 640.50 on the NSE at 3:10 pm, reflecting a 0.46% increase from the previous session's closing price. The drug Ivabradine is also indicated for children aged 6 months and older for treating stable symptomatic heart failure due to cardiomyopathy. 

The manufacturing of the drug will take place at Zydus Lifesciences' formulation facility in Ahmedabad. The company may be eligible for 180 days of shared generic exclusivity for Ivabradine Tablets, 5 mg, and 7.5 mg, as it was among the first abbreviated new drug application (ANDA) applicants with a substantially complete ANDA featuring a paragraph IV certification for Ivabradine Tablets, 5 mg, and 7.5 mg, according to Zydus Life's filing with the bourses. 

The stock has witnessed a 52.5% gain this year, outperforming Nifty's 11.42% rise during the same period.

Related Tags

  • Zydus Lifesciences
  • Zydus Lifesciences drugs
  • Zydus Lifesciences news
  • Zydus Lifesciences share price
  • Zydus Lifesciences Updates
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Most Read News

4 Mar 2024   |   09:10 AM
4 Mar 2024   |   06:22 PM
4 Mar 2024   |   08:40 AM
4 Mar 2024   |   06:37 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.